Compare
Harrow, Inc. vs Schrodinger, Inc. vs Evolus, Inc. vs CorMedix Inc.
| Latest fiscal year | Harrow, Inc. HROW | Schrodinger, Inc. SDGR | Evolus, Inc. EOLS | CorMedix Inc. CRMD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $272.30M | $255.87M | $297.18M | $311.71M |
| Revenue growth (YoY) | +36.4% | +23.3% | +11.6% | +617.0% |
| Gross margin | 75.1% | 55.7% | 66.3% | 88.5% |
| Operating margin | 11.2% | -65.2% | -11.0% | 48.2% |
| Net margin | -1.9% | -40.4% | -17.4% | 52.3% |
| Net income | -$5.14M | -$103.27M | -$51.64M | $163.06M |
| EPS (Diluted) | -$0.14 | -$1.41 | -$0.80 | $2.04 |
| Operating cash flow | $43.86M | $13.90M | -$42.27M | $175.05M |
| Free cash flow | $42.98M | $12.46M | -$45.71M | $172.79M |
| Cash & equivalents | $72.93M | $230.52M | $53.83M | $144.84M |
| Total assets | $399.48M | $726.16M | $225.87M | $826.14M |
| Total liabilities | $347.39M | $362.11M | $248.97M | $420.83M |
| Shareholders' equity | $52.45M | $364.05M | -$23.11M | $405.31M |
| Return on year-end equity | -9.8% | -28.4% | n/a | 40.2% |
| Shares outstanding | 37.23M | n/a | 65.01M | 79.26M |
Revenue, most recent five fiscal years
| Fiscal year | Harrow, Inc. | Schrodinger, Inc. | Evolus, Inc. | CorMedix Inc. |
|---|---|---|---|---|
| Latest | $272.30M Ended 2025-12-31 | $255.87M Ended 2025-12-31 | $297.18M Ended 2025-12-31 | $311.71M Ended 2025-12-31 |
| 1 year earlier | $199.61M Ended 2024-12-31 | $207.54M Ended 2024-12-31 | $266.27M Ended 2024-12-31 | $43.47M Ended 2024-12-31 |
| 2 years earlier | $130.19M Ended 2023-12-31 | $216.67M Ended 2023-12-31 | $202.09M Ended 2023-12-31 | n/a |
| 3 years earlier | $88.59M Ended 2022-12-31 | $180.96M Ended 2022-12-31 | $148.62M Ended 2022-12-31 | $65.4K Ended 2022-12-31 |
| 4 years earlier | $72.48M Ended 2021-12-31 | $137.93M Ended 2021-12-31 | $99.67M Ended 2021-12-31 | $190.9K Ended 2021-12-31 |